6. Parkinson disease Clinical trials / Disease details

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05116813 (ClinicalTrials.gov)	October 25, 2021	1/11/2021	Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy	An Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy With or Without Concomitant Dopaminergic Medications	Parkinson Disease;Dyskinesia, Drug-Induced;Dyskinesias	Drug: Dipraglurant	Addex Pharma S.A.	NULL	Recruiting	30 Years	85 Years	All	140	Phase 2/Phase 3	United States
2	NCT04857359 (ClinicalTrials.gov)	August 6, 2021	21/4/2021	Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy	Phase 2b/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Dipraglurant (ADX48621) for the Treatment of Dyskinesia in Patients With Parkinson's Disease Receiving Levodopa-based Therapy	Parkinson Disease;Dyskinesia, Drug-Induced;Dyskinesias	Drug: Dipraglurant;Drug: Placebo	Addex Pharma S.A.	NULL	Recruiting	30 Years	85 Years	All	140	Phase 2/Phase 3	United States
3	EUCTR2010-022517-25-DE (EUCTR)	30/05/2011	14/02/2011	Safety, tolerability and efficacy of ADX48621 in patients with Parkinson's disease	Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety, tolerability and efficacy of ADX48621 in the treatment of levodopa induced dyskinesia in patients with Parkinson's disease	Levodopa induced dyskinesia in Parkinson's disease patients MedDRA version: 13.1;Level: PT;Classification code 10013916;Term: Dyskinesia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: ADX48621 Product Code: ADX48621 INN or Proposed INN: Dipraglurant	Addex Pharma SA	NULL	Not Recruiting			Female: yes Male: yes	90	Phase 2	United States;France;Austria;Germany
4	EUCTR2010-022517-25-AT (EUCTR)	15/04/2011	17/02/2011	Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety, tolerability and efficacy of ADX48621 in the treatment of levodopa induced dyskinesia in patients with Parkinson's disease	Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety, tolerability and efficacy of ADX48621 in the treatment of levodopa induced dyskinesia in patients with Parkinson's disease	Levodopa induced dyskinesia in Parkinson's disease patients MedDRA version: 14.0;Level: PT;Classification code 10013916;Term: Dyskinesia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: ADX48621 Product Code: ADX48621 INN or Proposed INN: Dipraglurant	Addex Pharma SA	NULL	Not Recruiting			Female: yes Male: yes	90	Phase 2	United States;France;Austria;Germany
5	NCT01336088 (ClinicalTrials.gov)	April 2011	4/4/2011	ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease	Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ADX48621 in the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease	Parkinson's Disease	Drug: ADX48621;Drug: Placebo	Addex Pharma S.A.	NULL	Completed	30 Years	75 Years	Both	83	Phase 2	United States;Austria;France;Germany